Terms ending in 2029
Every in-force patent on Gilead Sciences, Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,334,295 | Pyrimidine Derivatives as HIV Reverse Transcriptase Inhibitors In force · High confidence | Korea Research Institute of Chemical Technology | In force | High confidence | |
| US 8,193,192 | Heterocyclic FXR Binding Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,569,478 | Modified 4`-NUCLEOSIDES as Antiviral Agents In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,217,155 | Metabolites and Derivatives of Ambrisentan In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 7,964,580 | Nucleoside Phosphoramidate Prodrugs In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 7,968,544 | Modulators of Toll-Like Receptor 7 In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 7,842,672 | Phosphonate Inhibitors of HCV In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 8,318,682 | 1'SUBSTITUTED Carba-Nucleoside Analogs for Antiviral Treatment In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US RE46,762 | 1'-Substituted Carba-Nucleoside Analogs for Antiviral Treatment In force · Low confidence | Gilead Sciences, Inc. | In force | Low confidence | |
| US 8,338,435 | Substituted PYRIDO(3,2-D) Pyrimidines and Pharmaceutical Compositions for Treating Viral Infections In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| 30 more term ends in 2029 · Pro | |||||
10 of 40 patents shown. Soonest term end first, then patent number.
Pro members see all 40.
39 of these are in force and held by Gilead Sciences, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.